JP2019516790A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516790A5
JP2019516790A5 JP2019510737A JP2019510737A JP2019516790A5 JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5 JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cyclopentyl
amino
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516790A (ja
JP6927548B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/083162 external-priority patent/WO2017193872A1/en
Publication of JP2019516790A publication Critical patent/JP2019516790A/ja
Publication of JP2019516790A5 publication Critical patent/JP2019516790A5/ja
Application granted granted Critical
Publication of JP6927548B2 publication Critical patent/JP6927548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510737A 2016-05-07 2017-05-05 ある種のタンパク質キナーゼ阻害剤 Active JP6927548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
US62/333,165 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2019516790A JP2019516790A (ja) 2019-06-20
JP2019516790A5 true JP2019516790A5 (enExample) 2020-04-09
JP6927548B2 JP6927548B2 (ja) 2021-09-01

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510737A Active JP6927548B2 (ja) 2016-05-07 2017-05-05 ある種のタンパク質キナーゼ阻害剤

Country Status (14)

Country Link
US (1) US10835535B2 (enExample)
EP (1) EP3452484B1 (enExample)
JP (1) JP6927548B2 (enExample)
KR (1) KR102374033B1 (enExample)
CN (1) CN109153686B (enExample)
AU (1) AU2017262155B2 (enExample)
CA (1) CA3023460A1 (enExample)
DK (1) DK3452484T3 (enExample)
ES (1) ES2954148T3 (enExample)
MX (1) MX387648B (enExample)
RU (1) RU2738837C2 (enExample)
TW (1) TWI752026B (enExample)
WO (1) WO2017193872A1 (enExample)
ZA (1) ZA201808238B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
JP5130305B2 (ja) 2007-02-15 2013-01-30 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしての2−アミノオキサゾリン
JP2010524972A (ja) 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
ES2564422T3 (es) 2007-11-15 2016-03-22 Ym Biosciences Australia Pty Ltd Compuestos heterocíclicos que contienen N
SI2331547T1 (sl) 2008-08-22 2014-11-28 Novartis Ag Pirolopirimidinske spojine kot CDK inhibitorji
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106795179B (zh) 2014-05-28 2019-09-17 锦州奥鸿药业有限责任公司 一类激酶抑制剂
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Similar Documents

Publication Publication Date Title
JP2019516790A5 (enExample)
JP2017504635A5 (enExample)
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
JP2017519781A5 (enExample)
RU2018143284A (ru) Некоторые ингибиторы протеинкиназы
JP2017525668A5 (enExample)
JP2013528204A5 (enExample)
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
HRP20220414T1 (hr) Inhibitori lizin specifične demetilaze-1
IL279800B2 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
JP2017502940A5 (enExample)
JP2017514830A5 (enExample)
JP2017521407A5 (enExample)
AU2008239655B2 (en) Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
JP2014504622A5 (enExample)
RU2015121374A (ru) Ингибиторы alk-киназы
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
JP2012501312A5 (enExample)
RU2016110096A (ru) Новое хинолин-замещенное соединение
HRP20181008T1 (hr) Terapeutski aktivni pirazolo-pirimidin derivati
JP2019512535A5 (enExample)
RU2016134751A (ru) Соединения
JP2016028076A5 (enExample)
JP2014500296A5 (enExample)